搜尋
Nervgen Pharma Ord Shs
NGEN添加自選
1.770USD
+0.095+5.67%
收盤 07-23 16:00（美東）報價延遲15分鐘
140.98M總市值
虧損本益比TTM
關於 Nervgen Pharma Ord Shs 公司
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Nervgen Pharma Ord Shs簡介
公司代碼NGEN
公司名稱NervGen Pharma Corp
上市日期Mar 13, 2019
CEORogers (Adam H)
員工數量- -
證券類型Ordinary Share
年結日- -
公司地址Suite 1703 - 595 Burrard Street
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編V7X 1J1
電話16047225361
網址https://www.nervgen.com/
公司代碼NGEN
上市日期Mar 13, 2019
CEORogers (Adam H)
Nervgen Pharma Ord Shs公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
-31.25%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
27.76K
-54.04%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Mr. John Craig Thompson
Mr. John Craig Thompson
Independent Director
Independent Director
--
--
Dr. Adam H. Rogers
Dr. Adam H. Rogers
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Gianni (John) Ruffolo
Mr. Gianni (John) Ruffolo
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
-31.25%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
27.76K
-54.04%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
常見問題
Nervgen Pharma Ord Shs的前五大股東是誰？
Nervgen Pharma Ord Shs的前五大股東如下：Dr. Randall E. Kaye, M.D.
有多少機構持有Nervgen Pharma Ord Shs(NGEN)的股份？
截至2026Q1，共有17家機構持有Nervgen Pharma Ord Shs的股份，合計持有的股份價值約為350.93K，占公司總股份的0.44% 。與2025Q4相比，機構持股有所增加，增幅為303132.00。